Antaros Medical methods at EASD on target engagement of the GIP-receptor and imaging of the heart and liver

September 21st, 2020

Today, the 56th annual meeting of the European Association for the study of diabetes (EASD) begins. There will be five full days focused on diabetes – a disease affecting over 400 million people world-wide (WHO).  We are looking forward to engaging with the diabetes community and to share some new, exciting data from Antaros Medical.

 

Antaros Medical, in collaboration with Sanofi, are presenting data on the development of a Positron Emission Tomography (PET) ligand for the receptor of the incretin hormone Gastric Inhibitory Polypeptide (GIP). Targeting of the GIP receptor (GIPR) is one of several emerging strategies in anti-diabetic drug development. The presented data shows promise for a novel PET biomarker for safe, non-invasive, and quantitative assessment of GIPR target distribution and engagement.

 

Title: In vivo PET imaging of the gastric inhibitory polypeptide receptor in pancreas

 

Authors: O. Eriksson, I. Velikyan, T. Haack, M. Bossart, A. Evers, I. Laitinen, O. Plettenburg, G. Antoni, L. Johansson, S. Pierrou, M. Wagner

Time: 23 September 2020, 12:00 – 13:00

Abstract number: 578

Session: PS 45 Basic aspects of incretin-based therapies

 

In addition, Antaros Medical has contributed to the AstraZeneca poster presenting additional, exploratory data from the DAPACARD trial. The poster will be presented orally on the 23rd of September.

 

Title: Effects of 6 weeks of treatment with dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, on myocardial function and metabolism in patients with type 2 diabetes

 

Authors: J. Oldgren, S. Laurila, A. Åkerblom, A. Latva-Rasku, E. Rebelos, H. Isackson1, M. Saarenhovi, O. Eriksson, K. Heurling, E. Johansson, U. Wilderäng, C. Karlsson, E. Ferrannini, J. Oscarsson, P. Nuutila;

Time: 23 September 2020, 15:15 – 15:30

Abstract number: 124

Session: OP 21 SGLT-2 inhibitors: at the heart of the matter

 

Link to EASD 2020 congress

 

Back to all news